Cyclacel Pharmaceuticals Inc (NASDAQ: CYCC) is having an incredibly strong start to the trading session this morning, and for good reason. The company announced the publication of findings surrounding Cyclin E1 that further validates its work with its CYC065 treatment. Today, we’ll talk about:
- The publication;
- what we’re seeing from CYCC stock as a result; and
- what we’ll be watching for ahead.
CYCC Announces Publication Surrounding Cyclin E1
As mentioned above, Cyclacel Pharmaceuticals is having an incredibly strong start to the trading session this morning after announcing the publication of data. In a press release issued early this morning, the company highlighted a paper from independent investigators.
The paper was titled, “Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor-Positive Metastatic Breast Cancer.” The paper was published in the Journal of Clinical Oncology and is available here.
Through the study, the independent investigators identified overexpression of cyclin E1 as a mechanism by which breast cancer escapes the efforts of palbociclib CDK4/5 inhibitor plus fulvestrant treatment.
This is important to CYCC investors as inhibition of the CDK2/cyclin E complex is the target of its CYC065 clincial stage candidate. The treatment is being developed as a potential therapeutic approach to prevent early progression on CDK4/6 inhibitors.
In a statement, Spiro Rombotis, President and CEO at CYCC, had the following to offer:
These data from a successful, randomized Phase 3 study identifies cyclin E as a biomarker of resistance of estrogen receptor positive, HER-2 negative breast cancer to palbociclib regimens. This supports and extends previous data showing that cyclin E is a resistance mechanism to HER-2 positive breast and uterine cancer treated with trastuzumab. Preclinical data demonstrated CYC065 activity in cyclin E amplified models of palbociclib-resistant breast cancer. Tumor shrinkage and stable disease were observed in four patients with cyclin E amplified advanced cancers in a first-in-human, Phase 1 study of single agent CYC065. Cyclin E amplified tumors are found in patients with gynecological and other cancers and represent a large, unmet medical need. The findings support CYC065’s broad therapeutic potential and unique target profile among CDK inhibitors.
What We’re Seeing From The Stock
One of the first lessons that we learn when we start to work in the market is that the news leads to moves. When it comes to Cyclacel Pharmaceuticals, the news proved to be overwhelmingly positive.
After all, the data that was published was compiled by a third party, yet validates the method of action of its candidate. As a result, there’s a stronger chance that the treatment may find its way to approval.
Considering this, it’s not surprising to see that excited investors are pushing the stock on a run for the top. As is just about always the case, our partners at Trade Ideas were the first to alert us to the gains. Currently (8:10), CYCC is trading at $1.28 per share after a gain of $0.34 per share or 36.17% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on CYCC. In particular, we’re interested in following the story surrounding the company’s continued work to bring CYC065 as well as the rest of its pipeline through the development process and to patients in need. Nonetheless, we’ll continue to follow the story closely and bring the news to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!